While complying with local directives, Cellecta is fully operational. Normal turnaround times have not been affected by COVID-19 more >
Wednesday, June 29, 2016
Tumor microenvironment is the current focus in cancer. Immune infiltrate in several human carcinoma types is implicated in prognosis and/or response to therapy. Molecular profiles of tumors and tumor-associated cells hold considerable promise as biomarkers of clinical outcomes. Considering each of these, Cellecta developed a novel DriverMap™ portfolio—a targeted expression profiling service that leverages the power of Multiplex PCR and NGS assays and allows you to obtain transcriptome analysis of your sample. It can be used to detect cellular composition, profile immunotherapy targets and, obtain expression analysis of ~8,000 genes. Join us for this webinar to learn about technology validation and intended applications
Sunitha Sastry, Ph.D., Senior Product Manager
Cellecta, Inc.
